Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Thejew on Mar 18, 2019 9:58pm

134 Views

Post# 29503872

RE:RE:Keep adding.

Results from the first cohort should be out any day now. Which are the lowest dose. Based on their, and in general CBDs safety profile, we can expect the results to get better and better as the strength is increased.

So the second and final cohort results should be out in the next few months and then full data read out probably in 3-5 months. If full data is good, I see this back in the .30sUS, bringing in a whopping 600% increase. I think it's well worth the wait.

IMHO!

Bullboard Posts

Two Venture-listed mining stocks file NI 43-101 reports